STOCK TITAN

Esperion Therape - ESPR STOCK NEWS

Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.

Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.

Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.

Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.

Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has appointed Stephen Rocamboli as a Class I director, filling a vacancy left by Dr. Mark McGovern’s retirement. Rocamboli, who has extensive experience in life sciences, is expected to enhance Esperion’s strategic direction as it commercializes its medicines and prepares for the upcoming CLEAR Outcomes trial readout in Q1 2023. CEO Sheldon Koenig expressed confidence in Rocamboli's contributions towards the commercialization of approved products and the development of new therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
management
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced the launch of the CLEAR ACS trial, aimed at evaluating the efficacy of NEXLIZET in reducing LDL-C in patients post-acute coronary syndrome (ACS). This 24-week study will recruit 500 patients, assessing the drug's safety and effectiveness in diverse, high-risk populations often underrepresented in clinical trials. The findings could significantly impact treatment protocols for LDL-C management. Key endpoints include changes in LDL-C levels and cardiovascular outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
none
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) plans to report its first-quarter 2022 financial results on May 3, 2022, before U.S. markets open. Following the announcement, management will discuss the results and business progress during a conference call at 8:00 a.m. ET. Interested parties can join the call by dialing (877) 831-3840 or (253) 237-1184, with an access code of 1489326. A live audio webcast will also be available on the Esperion website, along with a replay accessible two hours after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
conferences earnings
Rhea-AI Summary

Esperion has released positive pooled Phase 3 data demonstrating significant LDL-C reductions. Bempedoic acid monotherapy resulted in a 26.5% reduction versus placebo, while a fixed-dose combination of bempedoic acid and ezetimibe achieved a 39.2% reduction, both statistically significant (p<0.001). The study involved 427 participants, emphasizing lipid management for statin-intolerant patients. Ongoing trials like CLEAR Outcomes aim to enhance understanding of bempedoic acid’s efficacy. The findings suggest promise for patients unable to tolerate statins, marking a potential shift in cholesterol management strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
-
Rhea-AI Summary

Esperion presented significant clinical analyses for NEXLETOL (bempedoic acid) at the ACC.22 conference, highlighting its efficacy in lowering LDL-C in patients with renal impairment and hypertension. The analyses, covering over 3,600 patients, demonstrated significant LDL-C reductions (p<0.0001) across various patient groups. NEXLETOL is the first oral, once-daily non-statin LDL-C-lowering medication approved by the FDA in nearly two decades, supporting its use for adults with established cardiovascular disease or heterozygous familial hypercholesterolemia who need additional LDL-C lowering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the 21st Annual Needham Healthcare Conference on April 12, 2022. The event will feature a virtual fireside chat and 1:1 meetings, starting at 9:30 a.m. ET. Interested parties can access live audio webcasts on the investor relations section of the Esperion website. Replays will be available for 90 days following the event. Esperion is focused on lipid management, developing innovative medicines to lower cholesterol.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
conferences
Rhea-AI Summary

Esperion (NASDAQ: ESPR) will have its Chief Medical Officer, Dr. JoAnne Foody, participate in a Cardiometabolic/NASH panel at the Cowen 42nd Annual Healthcare Conference on March 8, 2022. This event will include one-on-one investor meetings and will be held in a virtual format starting at 12:50 p.m. ET. Live webcasts will be available on the company's investor relations website, with replays archived for 90 days post-event. Esperion focuses on lipid management and aims to provide innovative treatments for cholesterol reduction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
conferences
-
Rhea-AI Summary

Esperion reported a strong performance for Q4 2021, with U.S. net product revenue for NEXLETOL and NEXLIZET growing 12% sequentially to $12.2 million, a 200% increase for the full year. Prescriptions rose by 9%, reaching approximately 70,000 patients. The company strengthened its capital position with $209 million from equity financing, extending its cash runway to support the upcoming CLEAR Outcomes trial results.

Esperion anticipates significant operating expenses in 2022, with R&D expenses projected between $100 million to $110 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.54%
Tags
-
Rhea-AI Summary

Esperion (NASDAQ: ESPR) will announce its fourth quarter and full year 2021 financial results on February 22, 2022, before the U.S. market opens. The company will conduct a webcast and conference call at 8:00 a.m. ET to discuss the results and business progress, accessible via phone or on their website. Esperion focuses on innovating cholesterol-lowering medications, including NEXLETOL® and NEXLIZET® tablets, aimed primarily at patients inadequately served by existing treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
conferences earnings
Rhea-AI Summary

Esperion (NASDAQ: ESPR) granted stock options and restricted stock units (RSUs) to four new employees on January 27, 2022. Notably, Benjamin Looker, the new General Counsel, received options to purchase 100,450 shares at an exercise price of $3.65 per share and 70,800 RSUs. The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly. This granting aligns with the 2017 Inducement Equity Incentive Plan, aimed at attracting new talent to the company, which focuses on innovative cholesterol-lowering therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
Esperion Therape

Nasdaq:ESPR

ESPR Rankings

ESPR Stock Data

166.97M
197.15M
1%
65.72%
14.73%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR